| 14.01 0.93 (7.11%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.61 | 1-year : | 22.67 |
| Resists | First : | 16.79 | Second : | 19.41 |
| Pivot price | 15.31  |
|||
| Supports | First : | 12.55 | Second : | 10.44 |
| MAs | MA(5) : | 13.7 |
MA(20) : | 15.69 |
| MA(100) : | 17.17 |
MA(250) : | 19.57 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 10.4 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 30.97 | Low : | 12.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SMMT ] has closed above bottom band by 28.1%. Bollinger Bands are 17.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.19 - 14.25 | 14.25 - 14.31 |
| Low: | 12.79 - 12.85 | 12.85 - 12.9 |
| Close: | 13.91 - 14.01 | 14.01 - 14.1 |
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Sat, 13 Jun 2026
Summit Therapeutics files for $500M common stock offering; shares slide over 9% - MSN
Fri, 12 Jun 2026
SMMT Jumps As Ivonescimab Trial Success Fuels Financing Drive - StocksToTrade
Fri, 12 Jun 2026
Summit Therapeutics (NASDAQ: SMMT) investors approve directors and 8M-share incentive plan boost - Stock Titan
Fri, 12 Jun 2026
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares - Investing.com
Fri, 12 Jun 2026
Co-CEO Mahkam Zanganeh (SMMT) reports spouse’s 3.81M-share open-market buy - Stock Titan
Fri, 12 Jun 2026
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M St - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 776 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 82.6 (%) |
| Held by Institutions | 15.8 (%) |
| Shares Short | 29,820 (K) |
| Shares Short P.Month | 34,500 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -148.2 % |
| Return on Equity (ttm) | -271 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -384 (M) |
| Levered Free Cash Flow | 70 (M) |
| PE Ratio | -8.82 |
| PEG Ratio | 0 |
| Price to Book value | 16.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|